Cargando…

Prognostic utility of pre-operative circulating osteopontin, carbonic anhydrase IX and CRP in renal cell carcinoma

BACKGROUND: Objectively measured circulating biomarkers of prognosis complementing existing clinicopathological models are needed in renal cell carcinoma (RCC). METHODS: Blood samples collected from 216 RCC patients in Leeds before nephrectomy (median follow-up 7 years) were analysed for C-reactive...

Descripción completa

Detalles Bibliográficos
Autores principales:	Sim, S H, Messenger, M P, Gregory, W M, Wind, T C, Vasudev, N S, Cartledge, J, Thompson, D, Selby, P J, Banks, R E
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Nature Publishing Group 2012
Materias:	Molecular Diagnostics
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3461155/ https://www.ncbi.nlm.nih.gov/pubmed/22918393 http://dx.doi.org/10.1038/bjc.2012.360

Ejemplares similares

Pre-operative urinary cathepsin D is associated with survival in patients with renal cell carcinoma
por: Vasudev, N S, et al.
Publicado: (2009)

Hypoxia-regulated carbonic anhydrase IX expression is associated with poor survival in patients with invasive breast cancer
por: Hussain, S A, et al.
Publicado: (2007)

The prognostic impact of a combined carbonic anhydrase IX and Ki67 signature in oral squamous cell carcinoma
por: Klimowicz, A C, et al.
Publicado: (2013)

Alternative splicing variant of the hypoxia marker carbonic anhydrase IX expressed independently of hypoxia and tumour phenotype
por: Barathova, M, et al.
Publicado: (2008)

Measuring carbonic anhydrase IX as a hypoxia biomarker: differences in concentrations in serum and plasma using a commercial enzyme-linked immunosorbent assay due to influences of metal ions
por: Wind, Tobias C, et al.
Publicado: (2011)

High levels of carbonic anhydrase IX in tumour tissue and plasma are biomarkers of poor prognostic in patients with non-small cell lung cancer
por: İlie, M, et al.
Publicado: (2010)

Association of serum amyloid A protein and peptide fragments with prognosis in renal cancer
por: Wood, S L, et al.
Publicado: (2010)

Carbonic anhydrase IX is a predictive marker of doxorubicin resistance in early-stage breast cancer independent of HER2 and TOP2A amplification
por: Betof, A S, et al.
Publicado: (2012)

Endocervical glandular neoplasia associated with lobular endocervical glandular hyperplasia is HPV-independent and correlates with carbonic anhydrase-IX expression: a Gynaecological Oncology Group Study
por: Liao, S Y, et al.
Publicado: (2013)

Carbonic anhydrase IX (CA-IX) and high-risk human papillomavirus (H-HPV) as diagnostic biomarkers of cervical dysplasia/neoplasia in Japanese women with a cytologic diagnosis of atypical glandular cells (AGC): a Gynecologic Oncology Group (GOG) Study
por: Liao, S-Y, et al.
Publicado: (2011)

Improving the accuracy of pre-operative survival prediction in renal cell carcinoma with C-reactive protein
por: Jagdev, S P K, et al.
Publicado: (2010)

Nuclear osteopontin-c is a prognostic breast cancer marker
por: Zduniak, K, et al.
Publicado: (2015)

Expression of Osteopontin in oesophageal squamous cell carcinoma
por: Kita, Y, et al.
Publicado: (2006)

Expression of osteopontin coregulators in primary colorectal cancer and associated liver metastases
por: Mole, D J, et al.
Publicado: (2011)

Osteopontin is a marker for cancer aggressiveness and patient survival
por: Weber, G F, et al.
Publicado: (2010)

Suppression of tumour growth by orally administered osteopontin is accompanied by alterations in tumour blood vessels
por: Rittling, S R, et al.
Publicado: (2014)

Prognostic significance of osteopontin expression in early-stage non-small-cell lung cancer
por: Boldrini, L, et al.
Publicado: (2005)

Plasma osteopontin as a biomarker of prostate cancer aggression: relationship to risk category and treatment response
por: Thoms, J W, et al.
Publicado: (2012)

Early increase in circulating carbonic anhydrase IX: A potential new predictive biomarker of preeclampsia
por: Galbiati, Silvia, et al.
Publicado: (2023)

Wnt–β-catenin–Tcf-4 signalling-modulated invasiveness is dependent on osteopontin expression in breast cancer
por: Ravindranath, A, et al.
Publicado: (2011)

Combination of osteopontin and activated leukocyte cell adhesion molecule as potent prognostic discriminators in HER2- and ER-negative breast cancer
por: Ihnen, M, et al.
Publicado: (2010)

Soluble form of carbonic anhydrase IX (CA IX) in the serum and urine of renal carcinoma patients
por: Závada, J, et al.
Publicado: (2003)

Expression of carbonic anhydrase 9, a potential intrinsic marker of hypoxia, is associated with poor prognosis in oesophageal squamous cell carcinoma
por: Tanaka, N, et al.
Publicado: (2008)

Pre-treatment plasma proteomic markers associated with survival in oesophageal cancer
por: Kelly, P, et al.
Publicado: (2012)

miR-210 is a target of hypoxia-inducible factors 1 and 2 in renal cancer, regulates ISCU and correlates with good prognosis
por: McCormick, R I, et al.
Publicado: (2013)

Changes in tumour vessel density upon treatment with anti-angiogenic agents: relationship with response and resistance to therapy
por: Vasudev, N S, et al.
Publicado: (2013)

Detection of gastric cancer-associated microRNAs on microRNA microarray comparing pre- and post-operative plasma
por: Konishi, H, et al.
Publicado: (2012)

Systematic analysis of circulating soluble angiogenesis-associated proteins in ICON7 identifies Tie2 as a biomarker of vascular progression on bevacizumab
por: Zhou, Cong, et al.
Publicado: (2016)

Circulating tumour cells in the central and the peripheral venous compartment in patients with metastatic breast cancer
por: Peeters, D J E, et al.
Publicado: (2011)

Circulating Carbonic Anhydrase IX and Antiangiogenic Therapy in Breast Cancer
por: Brown-Glaberman, Ursa, et al.
Publicado: (2016)

Circulating fibrinogen is a prognostic and predictive biomarker in malignant pleural mesothelioma
por: Ghanim, B, et al.
Publicado: (2014)

Assessment of circulating biomarkers for potential pharmacodynamic utility in patients with lymphoma
por: Greystoke, A, et al.
Publicado: (2011)

Circulating biomarkers for detection of ovarian cancer and predicting cancer outcomes
por: Shapira, I, et al.
Publicado: (2014)

Circulating tumour markers can define patients with normal colons, benign polyps, and cancers
por: Mead, R, et al.
Publicado: (2011)

Identification of candidate circulating cisplatin-resistant biomarkers from epithelial ovarian carcinoma cell secretomes
por: Teng, P-N, et al.
Publicado: (2014)

Detection and prognostic significance of circulating tumour cells in patients with metastatic breast cancer according to immunohistochemical subtypes
por: Peeters, D J E, et al.
Publicado: (2014)

Diagnostic value of CA19.9, circulating tumour DNA and circulating tumour cells in patients with solid pancreatic tumours
por: Sefrioui, David, et al.
Publicado: (2017)

Detection of circulating tumour cells in peripheral blood with an automated scanning fluorescence microscope
por: Ntouroupi, T G, et al.
Publicado: (2008)

Increased mobilisation of circulating endothelial progenitors in von Hippel-Lindau disease and renal cell carcinoma
por: Bhatt, R S, et al.
Publicado: (2011)

Clinical significance of CDX2-positive circulating tumour cells in colorectal cancer patients
por: Wong, S C C, et al.
Publicado: (2011)

Cannot write session to /tmp/vufind_sessions/sess_i2846t2dl92jg4ea8qg2qtqffg